Skip to main content

Table 3 Antiviral activity of cervicovaginal lavage (CVL) against primary HIV-1 subtype C (97USNG30) in dual chamber system

From: Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties

 

HIV-1 Subtype C (97USNG30)

Animal

Day

10 TCID50

100 TCID50

IQP 1 (PMD2)

0

+

+

+

+

+

+

7

-

-

-

+

-

-

14

-

-

-

-

-

-

IQP 2 (PKP1)

0

+

+

+

+

+

+

7

+

-

+

+

+

+

14

-

-

+

+

+

+

IQP 3 (PHC2)

0

+

+

+

+

+

+

7

-

-

-

+

+

+

14

-

-

-

+

+

+

IQP 4 (PTE2)

0

+

+

+

+

+

+

7

+

-

+

+

+

+

14

-

-

-

-

-

-

Placebo 1 (PZA2)

0

+

+

+

+

+

+

7

+

+

+

+

+

+

14

+

+

+

+

+

+

Placebo 2 (PUG2)

0

+

+

+

+

+

+

7

+

+

+

+

+

+

 

14

+

+

+

+

+

+

  1. TZM-bl cells were exposed to CVL obtained at the indicated times (Day 0 (baseline), Day 7 or Day 14) from macaques treated with the IQP-0528 or placebo intravaginal ring and challenged with HIV (10 or 100 TCID50) in triplicate. Culture wells with luciferase activity above or below background levels from CVL exposure alone are marked (+) or (-), respectively.